Targeting HIF as a Promising Approach to Synergize With Immune Checkpoint Inhibitors

Documenti analoghi

• The CXCL12 – CXCR4 / CXCR7 axis as a therapeutic target in liver cancer: Enhancing immune evasion and the future of combination therapies
  di: Meiying Song, et al.
  Pubblicazione: (2026)
• Immune Signatures of Solid Tumor Patients Treated With Immune Checkpoint Inhibitors: An Observational Study
  di: Ling Chen, et al.
  Pubblicazione: (2024)
• Mutation in CDC42 Gene Set as a Response Biomarker for Immune Checkpoint Inhibitor Therapy
  di: Kun Wang, et al.
  Pubblicazione: (2025)
• The Addition of Concurrent Immune Checkpoint Inhibitors for Chemoradiotherapy With Consolidative Immune Checkpoint Inhibitors in Unresectable Cancers: A Systematic Review and Meta‐Analysis
  di: Xu Tong, et al.
  Pubblicazione: (2026)
• Peripheral Immune Cell Profiles as Predictive Biomarkers of Immune Checkpoint Inhibitor Efficacy in Elderly Patients With Advanced Non‐Small Cell Lung Cancer
  di: Shouzheng Wang, et al.
  Pubblicazione: (2025)